← Leaderboards
Aurora Esquela Kerscher
Yale University
$1,035,873
Attributed
$1,035,873
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $210.4K · FY2005–24$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,035,873 · 4
By mechanism
R21$750,673 · 2
R03$143,500 · 1
F32$141,700 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- James D Jamieson$32,787,611
- Lucia R Languino$10,651,281
- Cynthia Ann Brandt$12,415,934
- Margaret R Weeks$20,210,453
- Claudio R Alarcon$2,488,930
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsInnovationTissuesTumor ProgressionMalignant Neoplasm Of ProstateDiagnosisProstateProteinsUnited StatesOncogenicCessation Of LifeCell GrowthLiquid SubstanceCell LineMaleCellsLinkOrganAreaMolecularBiological MarkersCancer PatientApoptosisMouse Model
Grant awards (10)
Developing glycosylated RNAs as novel clinical targets for aggressive prostate cancer.$177,648
R21 · FY2024 · CA · contact PI
Developing glycosylated RNAs as novel clinical targets for aggressive prostate cancer.$1
R21 · FY2024 · CA · contact PI
Developing glycosylated RNAs as novel clinical targets for aggressive prostate cancer.$210,375
R21 · FY2023 · CA · contact PI
Role of the EPS Urine-Derived MicroRNA miR-888 in Prostate Cancer Progression$165,157
R21 · FY2015 · CA · contact PI
Role of the EPS Urine-Derived MicroRNA miR-888 in Prostate Cancer Progression$197,492
R21 · FY2014 · CA · contact PI
The Role of MicroRNAs in Prostate Cancer Progression$71,750
R03 · FY2010 · CA · contact PI
The Role of MicroRNAs in Prostate Cancer Progression$71,750
R03 · FY2009 · CA · contact PI
Characterization of Novel miRNAs During Development$50,428
F32 · FY2006 · GM · contact PI
Characterization of Novel miRNAs During Development$48,296
F32 · FY2005 · GM
Characterization of Novel miRNAs During Development$42,976
F32 · FY2004 · GM